Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
dc.contributor.author | Raymond, E | |
dc.contributor.author | Dahan, L | |
dc.contributor.author | Raoul, J | |
dc.contributor.author | Bang, Y | |
dc.contributor.author | Borbath, I | |
dc.contributor.author | Lombard-Bohas, C | |
dc.contributor.author | Valle, Juan W | |
dc.contributor.author | Metrakos, P | |
dc.contributor.author | Smith, D | |
dc.contributor.author | Vinik, A | |
dc.contributor.author | Chen, J | |
dc.contributor.author | Hörsch, D | |
dc.contributor.author | Hammel, P | |
dc.contributor.author | Wiedenmann, B | |
dc.contributor.author | Van Cutsem, E | |
dc.contributor.author | Patyna, S | |
dc.contributor.author | Lu, Dongr | |
dc.contributor.author | Blanckmeister, C | |
dc.contributor.author | Chao, R | |
dc.contributor.author | Ruszniewski, P | |
dc.date.accessioned | 2012-01-09T23:09:26Z | |
dc.date.available | 2012-01-09T23:09:26Z | |
dc.date.issued | 2011-02-10 | |
dc.identifier.citation | Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364 (6):501-13 N. Engl. J. Med. | en |
dc.identifier.issn | 1533-4406 | |
dc.identifier.pmid | 21306237 | |
dc.identifier.doi | 10.1056/NEJMoa1003825 | |
dc.identifier.uri | http://hdl.handle.net/10541/201093 | |
dc.description.abstract | The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. | |
dc.language.iso | en | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Disease Progression | |
dc.subject.mesh | Double-Blind Method | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Indoles | |
dc.subject.mesh | Intention to Treat Analysis | |
dc.subject.mesh | Kaplan-Meier Estimate | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neuroendocrine Tumors | |
dc.subject.mesh | Pancreatic Neoplasms | |
dc.subject.mesh | Proportional Hazards Models | |
dc.subject.mesh | Protein Kinase Inhibitors | |
dc.subject.mesh | Pyrroles | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Receptors, Vascular Endothelial Growth Factor | |
dc.title | Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. | en |
dc.type | Article | en |
dc.contributor.department | Service Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France. | en |
dc.identifier.journal | New England Journal of Medicine | en |
html.description.abstract | The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. |
This item appears in the following Collection(s)
-
All Christie Publications
-
Medical Oncology
Medical Oncology